Understanding Estriol: What We Know, What We Don't, and Its Role in Menopausal Hormone Therapy

Estriol is the least potent — and least studied — of the three main estrogens the body produces. It shows up often in compounded bi-est and tri-est prescriptions, but the evidence specific to estriol is thinner than many patients (and some marketing materials) suggest. This article lays out what is reasonably well established, what remains genuinely unresolved, and where a licensed prescriber's judgment has to fill the gap.

What is estriol?

The human body produces three principal estrogens: estrone (E1), estradiol (E2), and estriol (E3). Estradiol is the dominant, most biologically potent estrogen during the reproductive years. Estrone becomes relatively more prominent after menopause. Estriol is produced in large quantities during pregnancy — primarily by the placenta — and circulates at only low levels outside of pregnancy.

Compared with estradiol, estriol binds estrogen receptors more weakly and is generally considered a "weaker" estrogen in terms of receptor activity. That relative weakness is the basis for much of the interest in estriol for compounded hormone therapy: the theory is that a weaker estrogen may produce symptom relief with a different risk profile than estradiol alone. Whether that theoretical difference translates into a meaningfully different clinical outcome is exactly the kind of question that requires careful, cited evidence — see the review flag below.

Estriol in compounded formulations: bi-est and tri-est

Two compounded estrogen combinations commonly include estriol:

• Bi-est — typically a combination of estradiol and estriol, compounded in a prescriber-specified ratio (commonly discussed ratios include 80:20 and 50:50 estriol-to-estradiol, though the exact ratio is a prescribing decision, not a fixed standard).
• Tri-est — a combination of estrone, estradiol, and estriol, again in prescriber-specified proportions.

These are not FDA-approved fixed-dose drug products. They are patient-specific preparations, compounded under a valid prescription, and the ratios and total dose are set by the prescriber based on the individual patient — which is the same prescriber-directed model Pharmaprodia uses across its compounding services.

Professional guidance recognizes legitimate, individualized circumstances for compounded formulations generally — for example when a needed formulation, ingredient, or route is not commercially available, or when a patient has an intolerance to an ingredient in an FDA-approved product — while also noting that compounded products do not undergo the same FDA premarket review for safety, effectiveness and quality that FDA-approved medications do.^[4] Current ACOG guidance recommends FDA-approved menopausal hormone therapies over compounded preparations when an appropriate FDA-approved option is available, reserving compounding for situations where it is specifically needed.^[4]

What we reasonably know

• Estriol is a naturally occurring human estrogen with a well-characterized role in pregnancy physiology.
• Vaginally administered estriol (as opposed to systemic bi-est/tri-est) is often discussed as having a more established evidence base for genitourinary symptoms of menopause than systemic estriol use. In the United States, there are no FDA-approved drugs containing estriol — estriol-containing products marketed in the U.S., including those used vaginally, are compounded preparations rather than FDA-approved drugs.^[1][2]
• Most of the large-scale, long-term safety data that shapes menopausal hormone therapy guidance overall — most notably the Women's Health Initiative (WHI) hormone therapy trials — enrolled 27,347 postmenopausal women and studied conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day in women with a uterus, and CEE 0.625 mg/day alone in women with a prior hysterectomy.^[3] Estriol was not the estrogen studied in these WHI hormone therapy trials. Estriol's systemic safety profile is inferred from smaller and older studies, not from an equivalent large randomized trial.

What we don't know — and what shouldn't be claimed

There is not a robust body of large, long-term, randomized controlled trial evidence specific to systemic estriol (as used in bi-est or tri-est) that would support strong claims about superior safety compared with estradiol-based therapy — a conclusion consistent with the FDA's own current position that it does not have evidence that estriol-containing drugs are safer forms of estrogen.^[1] In particular:

• Estriol has not been demonstrated to prevent breast cancer. Any claim to that effect is not supported by current evidence and should not appear in Pharmaprodia patient-facing or marketing content.
• Estriol should not be characterized as universally "safer" than other forms of estrogen. Relative risk depends on dose, route of administration, duration of use, and the individual patient's health history — it is not a fixed property of the molecule that applies to every patient in every context.
• Long-term cardiovascular, breast, and endometrial outcome data specific to compounded bi-est/tri-est regimens are limited, which is one reason individualized monitoring and a prescriber relationship matter more than any general statement this article can make.
• More broadly, the FDA states it does not have evidence that compounded "bioidentical" hormone products — a category that includes estriol-containing preparations — are safer or more effective than FDA-approved hormone therapies.^[1] ACOG's clinical guidance similarly notes that high-quality evidence on the safety and efficacy of custom-compounded bioidentical menopausal hormone therapy is limited, and that "bioidentical" describes molecular similarity, not a demonstrated safety advantage.^[4] The Menopause Society likewise advises that custom-compounded hormone products should not be characterized as inherently safer or more effective, and notes that FDA-approved products can themselves be structurally identical to the hormones the body produces.^[5]

Clinical considerations

None of the following is a treatment recommendation. It illustrates the kinds of factors a prescriber typically weighs, so a patient can have a more informed conversation:

• Symptom pattern and severity (vasomotor symptoms, genitourinary symptoms, sleep and mood effects)
• Personal and family history relevant to hormone-sensitive conditions
• Route of administration (systemic vs. localized/vaginal) and how that changes the risk-benefit discussion
• Baseline and follow-up laboratory monitoring where clinically appropriate
• Duration of therapy and periodic reassessment

Because compounded formulations are prepared to a prescriber's specification rather than dispensed as a fixed commercial product, this individualized decision-making is central to how Pharmaprodia's prescription-care pathway works — see Prescription Care for how that process is structured.

The bottom line

Estriol is a real, naturally occurring hormone with a specific physiological role, and it has a legitimate place in some prescriber-directed compounded formulations. But the evidence base specific to estriol is smaller and less definitive than the evidence base for hormone therapy overall — and it does not currently support claims of cancer prevention or blanket superior safety.^[1][4][5] The honest answer to "is estriol right for me" is the same answer for most compounded hormone questions: it depends on the individual, and it's a conversation for a licensed prescriber, not a marketing claim.